查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1807528

寡核苷酸合成市场（按产品类型、合成规模、交付方式、应用和最终用户）—2025-2030 年全球预测

Oligonucleotide Synthesis Market by Product Type, Synthesis Scale, Delivery Method, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

寡核苷酸合成市场预计到 2024 年将达到 88.1 亿美元，到 2025 年将达到 102.8 亿美元，到 2030 年将达到 225.1 亿美元，复合年增长率为 16.91%。

主要市场统计数据
基准年2024年 88.1亿美元
预计2025年 102.8亿美元
预测年份 2030 225.1亿美元
复合年增长率（%） 16.91%

探索寡核苷酸合成的不断扩展的前沿领域，并深入了解产业驱动因素和新兴创新

寡核苷酸合成处于分子创新与商业性机会的交会点。随着研究应用从精准诊断扩展到下一代治疗，支持寡核苷酸生产的製程和技术正在快速发展。本报告的引言部分追溯了该领域从早期的手工合成到如今自动化、高通量平台的发展历程，为本文奠定了基础。

揭示重新定义寡核苷酸生产采用模式和技术突破的关键变革力量

寡核苷酸合成领域正在经历一场变革性的转变，其意义远不止于性能的提升。酶促方法的突破正在重新定义效率，使组装更长的寡核苷酸链并保持前所未有的保真度成为可能。同时，微阵列合成仪已从小众研究工具转变为主流工具，使高密度寡核苷酸文库的获取更加便利。

2025年美国关税对寡核苷酸供应链的累积影响：评估成本结构与市场动态

美国将于2025年加征新关税，进一步加剧了全球寡核苷酸供应链的复杂性。合成试剂、专用设备和客製化服务费将被征收额外关税，这实际上增加了下游应用的采购成本。为此，製造商和最终用户正在重新评估筹资策略，在免税地区寻找替代方案，并探索区域合作伙伴关係以减轻关税负担。

透过对寡核苷酸市场按产品尺寸、交付应用和最终用户进行全面分析，获得策略见解

对于寻求优化策略定位的相关人员来说，深入了解市场区隔至关重要。就产品类型而言，仪器和设备不断成熟，DNA/RNA合成仪为研究工作流程提供精确的输出，而微阵列平台则能够同时合成数千个独特序列。试剂和耗材是另一个支柱，涵盖从酵素混合物、标记剂到纯化化合物等各种产品。同时，软体和服务已成为重要的推动因素，生物资讯套件、云端基础管理解决方案和数据分析平台将原始序列数据转化为切实可行的洞察。同时，合成的寡核苷酸（无论是DNA或RNA）正在促进诊断、治疗等领域的应用，凸显了高纯度最终产品的重要性。

揭示美洲、欧洲、中东和非洲以及亚太地区寡核苷酸合成的区域动态

区域动态持续改变寡核苷酸合成的竞争格局。在美洲，先进的科学研究基础设施、协调一致的监管体係以及强劲的创业投资活动支撑着强劲的创新。从北美生物技术丛集到南美新兴中心，各大公司正增加对连接设计、合成和下游应用的整合平台的投资。

重点介绍塑造寡核苷酸合成生态系统的主要企业的竞争策略和创新者概况

寡核苷酸合成领域的竞争由成熟的跨国公司、敏捷的专业公司和新兴的生物技术公司主导。产业领导者投入了大量研发预算，以增强其仪器组合、扩展试剂产品线并整合先进的软体功能。这些投资使他们能够为高通量筛检和精准治疗设计提供端到端解决方案。

制定可行的建议，促进寡核苷酸产业的创新、协作和韧性，实现其永续发展

为了保持领先地位，产业相关人员应优先考虑整个合成价值链的协同创新。在设备製造商、试剂供应商和最终用户之间建立开放式创新伙伴关係，可以加速将实验室突破转化为可扩展的製程。这使得企业能够汇集资源、共用担风险，并共同打造针对新型应用（例如RNA疗法和照护现场）的解决方案。

了解我们严谨的调查方法，结合初步研究和次要研究，确保对寡核苷酸研究有深入的了解。

该分析基于一个全面的研究框架，该框架将一手资料研究与专家访谈以及来自同行评审日誌、专利资料库和监管出版物的二手资料分析相结合。一手资料研究包括对主要仪器製造商、试剂製造商、受託研究机构和最终用户组织的高级管理人员、研发总监和供应链经理的深入访谈。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 整合人工智慧预测分析来优化寡核苷酸的产量和纯度
  • 越来越多地采用酵素合成平台来高效生产长寡核苷酸
  • 扩大自动化微流体系统以实现高通量寡核苷酸组装
  • mRNA 疫苗前体需求的不断增长推动了寡核苷酸製造的进步
  • 开发多路復用合成阵列以支援个人化反义治疗流程
  • 即时製程分析技术增强寡核苷酸合成的品管
  • 扩展新型亚磷酰胺化学以提高偶联效率和保真度
  • 采用先进的酵素合成平台，高效组装用于治疗应用的长寡核苷酸
  • 开发高密度多重合成阵列以加速个人化反义寡核苷酸的管道开发
  • 整合机器学习演算法来预测和优化寡核苷酸合成结果，提高产量和纯度。

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 寡核苷酸合成市场（依产品类型）

  • 设备/器具
    • DNA/RNA合成器
    • 微阵列合成装置
  • 试剂和耗材
    • 酵素
    • 标记试剂
    • 纯化试剂
    • 合成试剂
  • 软体和服务
    • 生物资讯学工具
    • 云端储存和管理解决方案
    • 客製化寡核苷酸合成服务
    • 数据分析平台
  • 合成寡核苷酸
    • DNA寡核苷酸
    • RNA寡核苷酸

9. 寡核苷酸合成市场（依合成规模）

  • 客製化寡核苷酸合成
  • 大规模/商业化製造

第 10 章寡核苷酸合成市场（以交付方式）

  • 酵素合成
  • 固相合成

第11章寡核苷酸合成市场（依应用）

  • 诊断
    • 生物感测器
    • 分子影像
    • PCR和定序
  • 药物研发
    • 先导药物最适化
    • 目标检验
  • 调查
    • 功能基因体学
    • 基因表现分析
    • 基因合成
  • 治疗药物
    • 反义疗法
    • 基于CRISPR的疗法
    • RNA干扰

第 12 章寡核苷酸合成市场（依最终使用者）

  • 学术研究机构
  • 合约研究组织
  • 诊断实验室
  • 製药和生物技术公司

13. 美国寡核苷酸合成市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲寡核苷酸合成市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太寡核苷酸合成市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Agilent Technologies, Inc.
    • Ajinomoto Bio-Pharma Services
    • Bio-synthesis Inc.
    • LGC Genomics Limited
    • Danaher Corporation
    • Eurofins Genomics LLC
    • Eurogentec SA by Kaneka Corporation
    • GE HealthCare Technologies Inc.
    • Genscript Corporation
    • Merck KGaA
    • Nitto Denko Avecia Inc.
    • Thermo Fisher Scientific Inc.
    • Maravai Intermediate Holdings, LLC
    • Biolegio BV
    • Biolytic Lab Performance Inc.
    • Microsynth AG
    • parent added
    • PerkinElmer, Inc.
    • TAG Copenhagen A/S
    • Generi Biotech
    • Biocomma Ltd.
    • Hongene Biotech Corp.
    • TCI Chemicals（India）Pvt. Ltd.
    • Creative Biogene
    • Cusabio Technology LLC
    • Synbio Technologies
    • REPROCELL Inc.
    • Bon Opus Biosciences, LLC
    • Novartis AG

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-0A609A26A918

The Oligonucleotide Synthesis Market was valued at USD 8.81 billion in 2024 and is projected to grow to USD 10.28 billion in 2025, with a CAGR of 16.91%, reaching USD 22.51 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 8.81 billion
Estimated Year [2025] USD 10.28 billion
Forecast Year [2030] USD 22.51 billion
CAGR (%) 16.91%

Navigating the Expanding Frontiers of Oligonucleotide Synthesis with Insights into Industry Drivers and Emerging Technological Innovations

Oligonucleotide synthesis stands at the nexus of molecular innovation and commercial opportunity. As research applications expand from precision diagnostics to next-generation therapeutics, the processes and technologies underpinning oligonucleotide production have evolved rapidly. This report's introduction sets the stage by tracing the field's growth from early manual syntheses to today's automated, high-throughput platforms.

In recent years, heightened demand for custom DNA and RNA fragments has catalyzed advancements across the supply chain, from novel enzymatic pathways to sophisticated cloud-based bioinformatics. Concurrently, the integration of microarray synthesizers with real-time quality control has unlocked new capabilities in genomic profiling and personalized medicine. These technological leaps have been accompanied by shifts in stakeholder expectations, requiring manufacturers to deliver both speed and precision at scale.

Against this backdrop, our exploration begins with an overview of the regulatory, economic, and technological drivers that underpin current and future developments. By contextualizing the synthesis landscape within broader industry imperatives-such as data security, reproducibility, and cost optimization-we provide decision-makers with a clear line of sight on the challenges and opportunities ahead.

Through this foundational lens, readers will gain an appreciation for how incremental innovations converge to reshape end-to-end workflows, ultimately fostering a more agile, responsive, and quality-driven market environment.

Unveiling the Key Transformative Forces Redefining Oligonucleotide Production Adoption Patterns and Technological Breakthroughs

The oligonucleotide synthesis sector is experiencing transformative shifts that extend well beyond incremental performance gains. Breakthroughs in enzymatic methodologies are redefining efficiency, enabling the assembly of longer strands with unprecedented fidelity. At the same time, microarray synthesizers have transitioned from niche research instruments to mainstream tools that democratize access to high-density oligo libraries.

From an operational perspective, the advent of cloud-enabled design and data management platforms has bolstered collaboration across geographically dispersed research teams. These platforms facilitate seamless integration of bioinformatics tools with synthesis workflows, accelerating the translation of digital sequence data into physical molecules. Meanwhile, the rise of custom synthesis services has fragmented the traditional vendor landscape, empowering end-users to specify highly tailored delivery timelines and purity standards.

In parallel, the convergence of automation and artificial intelligence is driving smarter quality control processes, reducing error rates, and minimizing waste. Predictive analytics now play a critical role in optimizing reagent consumption and scheduling maintenance, thereby lowering total cost of ownership. Moreover, the deepening interplay between CRISPR-based genome editing applications and oligonucleotide manufacturing underscores a broader industry shift toward convergent innovation.

Taken together, these dynamics signal a fundamental realignment of value creation, where technological prowess, digital fluency, and service differentiation converge to define competitive advantage. Industry participants must therefore embrace cross-disciplinary collaboration and continuous process optimization if they intend to thrive in this rapidly evolving landscape.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Oligonucleotide Supply Chains Cost Structures and Market Dynamics

The imposition of new United States tariffs in 2025 has introduced a layer of complexity into global oligonucleotide supply chains. Synthesis reagents, specialized instruments, and custom service fees now carry additional duties that effectively increase procurement costs for downstream applications. In response, manufacturers and end-users have reevaluated their sourcing strategies, seeking alternatives in tariff-exempt jurisdictions and exploring regional partnerships to mitigate duty exposure.

Consequently, supply chain resilience has emerged as a focal point. Companies are diversifying their vendor base by engaging with regional producers in Europe, Asia-Pacific, and the Americas. This geographical rebalancing not only addresses tariff-related cost pressures but also reduces lead times for critical materials. At the same time, strategic inventory planning and forward-purchasing agreements have gained traction, enabling organizations to hedge against future rate adjustments.

The tariff landscape has also amplified the appeal of localized manufacturing infrastructure. Investment in domestic production facilities has accelerated, driven by incentives to avoid import levies and to align with broader reshoring initiatives. Through these investments, firms are forging deeper ties with domestic regulatory bodies and research institutions, fostering an ecosystem that prioritizes compliance, intellectual property security, and rapid innovation cycles.

As a result, stakeholders must navigate a more intricate compliance matrix, balancing cross-border trade risks against the benefits of scale and specialization. Those who proactively adapt to the new tariff regime will not only protect their margins but also unlock opportunities to forge new alliances and to exert greater control over critical supply chain nodes.

Deriving Strategic Insights from a Holistic Analysis of Oligonucleotide Market Segmentation across Product Scale Delivery Application and End-User

A nuanced understanding of market segmentation is essential for stakeholders aiming to optimize their strategic positioning. In the realm of product types, equipment and instruments continue to mature with DNA/RNA synthesizers delivering precise output for research workflows, while microarray platforms enable simultaneous synthesis of thousands of unique sequences. Reagents and consumables form another pillar, covering everything from enzymatic blends and labeling agents to purification compounds. Meanwhile, software and services have emerged as indispensable enablers, with bioinformatics suites, cloud-based management solutions, and data analysis platforms transforming raw sequence data into actionable insights. In parallel, synthesized oligonucleotides-whether DNA or RNA-fuelling applications in diagnostics, therapeutics, and beyond, underscore the centrality of high-purity end products.

Turning to synthesis scale, the dichotomy between custom protocols and large-scale manufacturing highlights differing operational imperatives. Custom providers excel at meeting bespoke sequence requirements and expedited timelines, whereas commercial-scale facilities leverage automation and volume efficiencies to serve broader therapeutic and diagnostic markets. Delivery methods further differentiate market offerings, as solid-phase synthesis remains the gold standard for reliability, while enzymatic approaches promise greener processes and reduced chemical waste.

In application contexts, diagnostics is witnessing robust adoption of oligos in biosensors, molecular imaging, and PCR-based assays, each demanding specific length, purity, and functional modifications. The drug discovery and development segment relies on lead optimization and target validation workflows to refine candidate molecules, often requiring high-throughput screening libraries. Research applications span functional genomics, gene expression analysis, and full gene synthesis, all of which depend on rapid turnaround times and consistent quality. Therapeutic avenues, such as antisense therapies, CRISPR-based interventions, and RNA interference, are driving demand for specialized chemistries and scale.

Finally, end-users encompass academic and research institutes that prioritize flexibility, contract research organizations that demand scalability and quality assurance, diagnostic laboratories that require validated reagents, and pharmaceutical and biotechnology companies that focus on regulatory compliance and large-volume deliveries. These intertwined segmentation layers illustrate the diversity of market requirements and the necessity for tailored value propositions.

Unraveling Regional Dynamics in the Oligonucleotide Synthesis Landscape across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics continue to reshape the competitive landscape of oligonucleotide synthesis. In the Americas, a combination of advanced research infrastructure, regulatory harmonization, and strong venture capital activity underpins robust innovation. From North American biotech clusters to emerging hubs in South America, organizations are increasingly investing in integrated platforms that bridge design, synthesis, and downstream applications.

Meanwhile, Europe, the Middle East, and Africa exhibit a rich tapestry of collaborative research networks. The European Union's emphasis on Horizon funding and cross-border interoperability has spurred joint ventures among academic centers and commercial entities. At the same time, Middle Eastern initiatives are focusing on biosecurity and diagnostics capacity-building, and African markets are exploring point-of-care solutions that leverage oligonucleotide-based assays for infectious disease surveillance.

Asia-Pacific has rapidly emerged as a powerhouse, driven by large-scale manufacturing capabilities, favorable government incentives, and a growing base of skilled life-science professionals. From contract manufacturers in China to innovation clusters in Singapore, regional players are capitalizing on production efficiencies and cost advantages. Simultaneously, domestic R&D investments in countries such as Japan, South Korea, and Australia are generating advanced applications in gene editing and RNA therapeutics.

As a result, each region presents distinct opportunities and challenges-ranging from intellectual property protection and regulatory alignment to talent acquisition and infrastructure development. Market participants must therefore calibrate their regional strategies to local realities, forging partnerships that leverage comparative strengths while addressing potential barriers to entry.

Highlighting Competitive Strategies and Innovator Profiles of Leading Companies Shaping the Oligonucleotide Synthesis Ecosystem

The competitive arena of oligonucleotide synthesis is defined by a spectrum of established multinational corporations, agile specialist players, and emerging biotechnology firms. Industry leaders have leveraged significant R&D budgets to enhance their instrument portfolios, broaden their reagent offerings, and integrate advanced software capabilities. These investments have enabled them to deliver end-to-end solutions that address both high-throughput screening and precision therapeutic design.

Mid-tier companies have carved out niches by focusing on high-purity custom syntheses, rapid turnaround services, and specialized chemistries. They often differentiate themselves through closer client engagement, streamlined regulatory support, and collaborative product development. Meanwhile, smaller innovators are exploring enzymatic approaches to synthesis, novel purification techniques, and AI-driven predictive analytics to challenge traditional paradigms.

Across this spectrum, partnerships and acquisitions remain a central theme. Leading instrument manufacturers have acquired bioinformatics startups to unify digital design with physical production, while reagent producers have forged alliances with academic consortia to co-develop next-generation labeling and modification reagents. Contract research organizations continue to invest in capacity expansion, anticipating growing demand for outsourced synthesis and analytical services.

Collectively, these competitive strategies underscore the importance of adaptability, cross-disciplinary collaboration, and a relentless focus on quality. Players that successfully align their R&D roadmaps with evolving customer requirements-while maintaining cost discipline and regulatory compliance-will command the greatest influence in shaping the market's trajectory.

Formulating Actionable Recommendations to Propel Innovation Collaboration and Resilience within the Oligonucleotide Industry for Sustained Growth

To maintain a leadership position, industry stakeholders should prioritize collaborative innovation across the synthesis value chain. Establishing open innovation partnerships between instrument makers, reagent suppliers, and end-users can accelerate the translation of laboratory breakthroughs into scalable processes. In doing so, companies can pool resources, share risk, and co-create solutions tailored to emerging applications such as RNA therapeutics and point-of-care diagnostics.

Furthermore, investing in digital ecosystems will enhance operational agility. By integrating predictive analytics, real-time monitoring, and cloud-based design tools, organizations can optimize yield, reduce production bottlenecks, and respond rapidly to shifts in demand. These digital levers should be complemented by robust quality management systems that adhere to evolving regulatory expectations in key markets.

Diversification of manufacturing footprints is equally critical. Leaders should evaluate strategic site expansions in tariff-exempt regions and develop contingency plans for potential trade disruptions. Such geographic flexibility not only mitigates cost volatility but also supports localized service delivery, strengthening customer relationships and supply chain resilience.

Finally, workforce development must remain a top priority. Cultivating a talent pool with expertise in synthetic biology, bioinformatics, and regulatory science will equip companies to navigate complex technical challenges. By fostering a culture of continuous learning and cross-functional collaboration, organizations can drive sustained innovation, minimize time to market, and secure competitive differentiation.

Detailing Rigorous Research Methodology Combining Primary Engagements and Secondary Analyses to Ensure Robust Insights in Oligonucleotide Studies

This analysis is grounded in a comprehensive research framework combining primary engagements with subject-matter experts and secondary data analyses from peer-reviewed journals, patent databases, and regulatory publications. Primary research included in-depth interviews with senior executives, R&D directors, and supply chain managers across major instrument manufacturers, reagent producers, contract research organizations, and end-user institutions.

Secondary research involved a systematic review of scientific literature, technical white papers, and conference proceedings, supplemented by data from public filings and government reports. Patent landscaping exercises were conducted to identify emerging technological trends and competitive positioning. Additionally, regulatory databases were mined to track recent approvals, guidelines, and compliance developments affecting synthesis processes.

Data triangulation was employed to validate insights, cross-referencing qualitative interview findings with quantitative performance metrics where available. Analytical techniques such as SWOT assessments, value chain mapping, and scenario planning underpinned the study's strategic conclusions. Peer reviews from external advisors and iterative feedback loops with industry participants further enhanced the robustness and relevance of the final deliverable.

This rigorous methodology ensures that the report's insights reflect both the current state of the market and forward-looking perspectives, equipping stakeholders with a reliable foundation for strategic decision-making.

The oligonucleotide synthesis market is characterized by rapid technological advances, evolving regulatory landscapes, and shifting trade dynamics. From the integration of cloud-based bioinformatics to the pursuit of greener enzymatic synthesis routes, the sector is poised for both incremental and disruptive change. Regional variations, particularly in the Americas, EMEA, and Asia-Pacific, underscore the necessity for tailored strategies that address local regulatory, economic, and infrastructural realities.

Segmentation analysis reveals that differentiated value propositions-in instrumentation, reagent portfolios, software capabilities, and service models-will drive future competitiveness. End-user demands for precision, speed, and cost-effectiveness continue to accelerate adoption across diagnostics, drug discovery, research, and therapeutic development.

Looking ahead, the firms that excel will be those that seamlessly integrate digital and physical workflows, diversify their geographic footprints, and cultivate deep partnerships across the value chain. Investment in workforce development, sustainable processes, and adaptive quality systems will serve as key enablers of growth.

Ultimately, a strategic focus on collaborative innovation, supply chain resilience, and regulatory foresight will define the next chapter of oligonucleotide synthesis. Organizations that embrace these imperatives will be best positioned to transform scientific potential into tangible solutions that address critical healthcare and research challenges.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of AI-driven predictive analytics to optimize oligonucleotide yield and purity
  • 5.2. Growing adoption of enzymatic synthesis platforms to streamline long oligonucleotide production
  • 5.3. Scale-up of automated microfluidic systems for high-throughput oligonucleotide assembly
  • 5.4. Rising need for mRNA vaccine precursors fueling advancements in oligonucleotide manufacturing
  • 5.5. Development of multiplexed synthesis arrays to support personalized antisense therapeutic pipelines
  • 5.6. Real-time process analytical technologies enhancing quality control in oligonucleotide synthesis
  • 5.7. Expansion of novel phosphoramidite chemistries to improve coupling efficiency and fidelity
  • 5.8. Adoption of advanced enzymatic synthesis platforms enabling efficient long-chain oligonucleotide assembly for therapeutics
  • 5.9. Development of high-density multiplexed synthesis arrays to accelerate personalized antisense oligonucleotide pipeline development
  • 5.10. Integration of machine learning algorithms to predict and optimize oligonucleotide synthesis outcomes for enhanced yield and purity

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Oligonucleotide Synthesis Market, by Product Type

  • 8.1. Introduction
  • 8.2. Equipment/Instruments
    • 8.2.1. DNA/RNA Synthesizers
    • 8.2.2. Microarray Synthesizers
  • 8.3. Reagents & Consumables
    • 8.3.1. Enzymes
    • 8.3.2. Labeling Reagents
    • 8.3.3. Purification Reagents
    • 8.3.4. Synthesis Reagents
  • 8.4. Software & Services
    • 8.4.1. Bioinformatics Tools
    • 8.4.2. Cloud Storage & Management Solution
    • 8.4.3. Custom Oligo Synthesis Services
    • 8.4.4. Data Analysis Platforms
  • 8.5. Synthesized Oligonucleotides
    • 8.5.1. DNA Oligonucleotides
    • 8.5.2. RNA Oligonucleotides

9. Oligonucleotide Synthesis Market, by Synthesis Scale

  • 9.1. Introduction
  • 9.2. Custom Oligonucleotide Synthesis
  • 9.3. Large-Scale/Commercial Manufacturing

10. Oligonucleotide Synthesis Market, by Delivery Method

  • 10.1. Introduction
  • 10.2. Enzymatic Synthesis
  • 10.3. Solid-Phase Synthesis

11. Oligonucleotide Synthesis Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnostics
    • 11.2.1. Biosensors
    • 11.2.2. Molecular Imaging
    • 11.2.3. PCR & Sequencing
  • 11.3. Drug Discovery & Development
    • 11.3.1. Lead Optimization
    • 11.3.2. Target Validation
  • 11.4. Research
    • 11.4.1. Functional Genomics
    • 11.4.2. Gene Expression Analysis
    • 11.4.3. Gene Synthesis
  • 11.5. Therapeutics
    • 11.5.1. Antisense Therapy
    • 11.5.2. CRISPR-Based Therapeutics
    • 11.5.3. RNA Interference

12. Oligonucleotide Synthesis Market, by End-User

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Contract Research Organizations
  • 12.4. Diagnostic Laboratories
  • 12.5. Pharmaceutical & Biotechnology Companies

13. Americas Oligonucleotide Synthesis Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Oligonucleotide Synthesis Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Oligonucleotide Synthesis Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Agilent Technologies, Inc.
    • 16.3.2. Ajinomoto Bio-Pharma Services
    • 16.3.3. Bio-synthesis Inc.
    • 16.3.4. LGC Genomics Limited
    • 16.3.5. Danaher Corporation
    • 16.3.6. Eurofins Genomics LLC
    • 16.3.7. Eurogentec S.A. by Kaneka Corporation
    • 16.3.8. GE HealthCare Technologies Inc.
    • 16.3.9. Genscript Corporation
    • 16.3.10. Merck KGaA
    • 16.3.11. Nitto Denko Avecia Inc.
    • 16.3.12. Thermo Fisher Scientific Inc.
    • 16.3.13. Maravai Intermediate Holdings, LLC
    • 16.3.14. Biolegio B.V.
    • 16.3.15. Biolytic Lab Performance Inc.
    • 16.3.16. Microsynth AG
    • 16.3.17. parent added
    • 16.3.18. PerkinElmer, Inc.
    • 16.3.19. TAG Copenhagen A/S
    • 16.3.20. Generi Biotech
    • 16.3.21. Biocomma Ltd.
    • 16.3.22. Hongene Biotech Corp.
    • 16.3.23. TCI Chemicals (India) Pvt. Ltd.
    • 16.3.24. Creative Biogene
    • 16.3.25. Cusabio Technology LLC
    • 16.3.26. Synbio Technologies
    • 16.3.27. REPROCELL Inc.
    • 16.3.28. Bon Opus Biosciences, LLC
    • 16.3.29. Novartis AG

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. OLIGONUCLEOTIDE SYNTHESIS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. OLIGONUCLEOTIDE SYNTHESIS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCHAI
  • FIGURE 26. OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCHCONTACTS
  • FIGURE 28. OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA/RNA SYNTHESIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA/RNA SYNTHESIZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MICROARRAY SYNTHESIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MICROARRAY SYNTHESIZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LABELING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LABELING REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PURIFICATION REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PURIFICATION REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CLOUD STORAGE & MANAGEMENT SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CLOUD STORAGE & MANAGEMENT SOLUTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGO SYNTHESIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGO SYNTHESIS SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA OLIGONUCLEOTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA OLIGONUCLEOTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LARGE-SCALE/COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LARGE-SCALE/COMMERCIAL MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PCR & SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PCR & SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ANTISENSE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ANTISENSE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CRISPR-BASED THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CRISPR-BASED THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 193. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 237. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 239. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 245. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 257. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 258. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 261. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 263. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 265. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 266. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 267. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 268. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 269. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 270. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 271. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 272. ARGENTINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED KINGDOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED KINGDOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED KINGDOM OLIGONUC